EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

North American study and meta-analysis evaluating performance of Bladder EpiCheck ® , a FDA cleared test, in non-muscle invasive bladder cancer recurrence

Neil Fleshner, Herbert Barton Grossman, Ryan Berglund, Jason Hafron, Brant Inman, Lawrence Karsh, Kelvin Moses, Daniel Saltzstein, Anup Shah, Jonathan Wright, Johannes Alfred Witjes, Yair Lotan

Bladder Cancer · 2024-12 · 10 (4) · 278-289

DOI: 10.1177/23523735241304348 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Bladder Cancer, online erschienen am 15.01.2025. Verfasst von Neil Fleshner und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, University Health Network, Toronto, Canada. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Nucleix.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bladder EpiCheck (BE) is a novel methylation-based PCR urine test for the detection of non-muscle invasive bladder cancer (NMIBC) recurrences.

Objective

We present the results of a North American study evaluating BE and meta-analysis of literature.

Methods

A prospective, blinded, multicenter study was conducted in North America. Voided urine was collected from NMIBC patients prior to cystoscopic surveillance. BE testing was performed centrally. For the meta-analysis, a PUBMED search was performed to identify all published peer-reviewed clinical studies of BE for NMIBC surveillance.

Results

In this study, 674 patients were enrolled of which 449 were included. Overall sensitivity was 67% (95%CI 58%-74%), specificity was 84% (80%-88%), PPV was 65% (57%-73%) and NPV was 85% (81%-89%). For high-grade (HG) recurrence, sensitivity was 77% (65%-85%) and NPV was 95% (92%-97%). In patients with negative cystoscopy and cytology at the first study visit, risk of subsequent recurrence in 12 months was 5.3 (2.7–10.3) times higher in patients with positive BE vs. negative BE (p < 0.0001). In patients with negative cystoscopy and equivocal cytology, BE was positive in 75–89% of those with later HG recurrence, with PPV of 42% (15%-72%)-63% (38%-84%). The meta-analysis included 7 studies and 1564 patients. Overall sensitivity was 82% (66–92%), HG sensitivity was 91% (82–95%), specificity was 85% (80–88%), PPV was 60% (55–64%) and HG NPV was 98% (97–99%).

Conclusions

The consistently strong performance of BE indicate that a positive test could improve timely disease recurrence detection and a negative test could rule-out HG disease. Furthermore, the low rate of false positive results, potentially minimizes unnecessary downstream procedures and patient anxiety.

Schlagwörter

Stichwörter der Autor:innen

biomarkerslocal [C04.697.655]neoplasm recurrencenon-muscle invasive bladder neoplasms [C04.588.945.947.960.500]non-muscle invasive bladder neoplasms [C12.900.820.945.500]real-Time polymerase chain reaction [E05.393.620.500.706]tumor [D23.101.140]urine [A12.207.927]

Autor:innen und Institutionen

  • Division of Urology, University Health Network, Toronto, Canada.
  • Retired, Bellaire, TX, USA.
  • Division of Urology, Cleveland Clinic, Cleveland, OH, USA.
  • Michigan Institute of Urology, Troy, MI, USA.
  • Department of Surgery, Division of Urology, Western University, London, Ontario, Canada.
  • The Urology Center of Colorado, Denver, Colorado, USA.

Förderung

  • Nucleix

Zitieren

APA

Fleshner, N., Grossman, H. B., Berglund, R., Hafron, J., Inman, B., Karsh, L., Moses, K., Saltzstein, D., Shah, A., Wright, J., Witjes, J. A., & Lotan, Y. (2024). North American study and meta-analysis evaluating performance of Bladder EpiCheck ® , a FDA cleared test, in non-muscle invasive bladder cancer recurrence. Bladder Cancer, 10(4), 278-289. https://doi.org/10.1177/23523735241304348

Vancouver

Fleshner N, Grossman HB, Berglund R, Hafron J, Inman B, Karsh L, et al. North American study and meta-analysis evaluating performance of Bladder EpiCheck ® , a FDA cleared test, in non-muscle invasive bladder cancer recurrence. Bladder Cancer. 2024;10(4):278-289. doi:10.1177/23523735241304348

BibTeX
@article{Fleshner2024,
  author = {Fleshner, Neil and Grossman, Herbert Barton and Berglund, Ryan and Hafron, Jason and Inman, Brant and Karsh, Lawrence and Moses, Kelvin and Saltzstein, Daniel and Shah, Anup and Wright, Jonathan and Witjes, Johannes Alfred and Lotan, Yair},
  title = {North American study and meta-analysis evaluating performance of Bladder EpiCheck ® , a FDA cleared test, in non-muscle invasive bladder cancer recurrence},
  journal = {Bladder Cancer},
  year = {2024},
  volume = {10},
  number = {4},
  pages = {278--289},
  doi = {10.1177/23523735241304348}
}
Kostenlos starten →